| Literature DB >> 22805113 |
Jong-In Kim1, Jun-Yong Choi, Dong-Hyo Lee, Tae-Young Choi, Myeong Soo Lee, Edzard Ernst.
Abstract
BACKGROUND: Complementary and alternative medicine (CAM) has frequently been used to treat tinnitus, and acupuncture is a particularly popular option. The objective of this review was to assess the evidence concerning the effectiveness of acupuncture as a treatment for tinnitus.Entities:
Mesh:
Year: 2012 PMID: 22805113 PMCID: PMC3493359 DOI: 10.1186/1472-6882-12-97
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Summary of randomized controlled trials of acupuncture for the treatment of tinnitus
| Hansen (1982) [ | 17 unilateral tinnitus | 46 (9/8) | (A) AT (15 min, 2 times weekly for 3 weeks, n = 17) | (B) Sham AT (Penetrating, non-acupoints, 15 min, 2 times weekly for 3 weeks, n = 17) | Period index (ND with usual tinnitus + 2×ND with usual tinnitus + 3×ND with more pronounced tinnitus) | MD, 2.8 [-3.95, 9.55] | Cross-over |
| | | 5.3 | | | | | Denmark |
| Vilholm (1998) [ | 53 severe tinnitus (both lesion) | 53 (35/19) | (A) AT (30 min, total 25 treatment sessions over two months, n = 29) | (B) Sham AT (Penetrating, minimal, non-acupoints, 30 min, total 25 treatments over two months, n = 25) | 1) Annoyance (VAS) | 1) MD, -5.0 [-21.26, 11.26] | Parallel |
| | | 9.1 | | | 2) Loudness (VAS) | 2) MD, -3.40 [-16.66, 9.86] | Denmark |
| | | | | | 3) Awareness (VAS) | 3) MD, -2.00 [-18.50, 14.50] | |
| Jeon (2012) [ | 33 unilateral tinnitus | A: 43.5 (13/4) | (A) AT (10min, 2 times weekly for 5 weeks, n = 17) | (B) Sham AT (Penetrating non acupoints, 10min, 2 times weekly for 5 weeks, n = 16) | 1) Tinnitus Handicap Inventory score | 1) Post, MD, 0.5 [-14.1, 15.1],NS | Parallel |
| | | B: 49.6 (8/8) | | | 2) Symptom I(VAS) | 3mo, MD, -2.5 [-15.5,10.5], NS | Korea |
| | | A: 37.4 | | | | 2) Post, MD, -9.5 [-23.9, 4.9], NS | |
| | | B: 45.6 | | | | 3mo, MD, -12.5 [-27.0, 2.0], NS | |
| Wang (2010) [ | 50 tinnitus (n.r.) | 30-70 (46/4) | (A) AT (25 min, once a week for 6 weeks, total 6 treatments, n = 19) | (C) Sham AT (Penetrating, minimal, non-acupoints, 25 min, once a week for 6 weeks, n = 15) | 1) Subjective general evaluation of the treatments | 1) A vs. C, MD, -0.02 [-0.12, 0.09], NS | Parallel |
| | | n.r. | (B) EA (alternative frequency of 2/100 Hz at 3 s interval, 25 min, once a week for 6 weeks, total 6 treatments, n = 16) | | 2) Tinnitus occurrence | B vs. C, MD, 0.32 [0.24, 0.39], P < 0.0001 | Denmark |
| | | | | | 3) Tinnitus loudness | 2) NS† | |
| | | | | | 4) Quality reduction of daily life | 3) NS† | |
| | | | | | 5) Effect on the hearing improving | 4) NS† | |
| | | | | | | 5) NS† | |
| Marks (1984) [ | 14 chronic unilateral tinnitus | 51 (7/7) | (A) EA with (20 min, once weekly for two weeks, n = 14) | (B) Sham AT (Non-penetrating, non-acupoints, pricking and direct removal, once weekly for two weeks, n = 14) | 1) Loudness at a particular time, loudness taking the day as a whole (VAS) | 1) NS† | Cross-over |
| | | n.r. | | | 2) Response rate (verbal description of any changes) | 2) NS† | UK |
| | | | | | 3) Tinnitus matching score | 3) NS† | |
| Okada (2006) [ | 76 tinnitus (n.r.) | 57 (29/47) | (A) Scalp AT (manual rotation at 2 Hz, 15 seconds, one time, n = 38) | (B) Sham scalp AT (Penetrating, non-acupoints, manual rotation at 2 Hz, 15 seconds, one time, n = 38) | Subjective symptom relief (VAS) | MD, -1.34 [-2.48, -0.21], P = 0.02 in favor of A | Parallel |
| | | n.r. | | | | | Brazil |
| de Azevedo (2007) [ | 38 tinnitus (n.r.) | 36-76 (13/25) | (A) Scalp AT (manual rotation at 2 Hz, 15 seconds, one time, n = 19) | (B) Sham scalp AT (Penetrating, non-acupoints, manual rotation at 2 Hz, 15 seconds, one time, n = 19) | Otoacoustic emission amplitude | AT on the left side | Parallel |
| | Parallel | n.r. | | | | - Right side: 3.39 [-1.53, 8.31], NS | Brazil |
| | | | | | | - Left side: 1.35 [-3.29, 5.99], NS | |
| | | | | | | AT on the right side | |
| | | | | | | - Right side: 3.16[-0.99, 5.99], NS | |
| | | | | | | - Left side: 1.56 [-2.21, 5.33], NS | |
| Tan (2007) [ | 90 nervous tinnitus (n.r.) | 18-65 (48/42) | (A) AT (de-qi, 1 session = 20 min, daily,10 times, total 3 sessions, total 30 treatments, n = 30) | (B) Drug therapy (Bandazol, Dextran 40, Danshen tablet, and vitamin B12, 10 days, total 3 sessions, n = 30) | Response rate (verbal description of any changes) | RR, 2.20 [1.27, 3.89], P < 0.05 | Parallel |
| | | 1 week-10years | | | | China | |
| Jiang (2010) [ | 60 senile tinnitus (n.r.) | 50-80 (21/39) | (A) AT (n.r., 1 session = 30 min, once daily, 5 times, rest for 2 days, 10 times/session, total 3 sessions, total 30 treatments, n = 30) | (B) Drug therapy (Flunarizine hydrochloride 10mg, orally at bedtime, 4weeks, stop taking without any improvements, effective service by adding 2 weeks, n = 30) | 1) Hearing-threshold detection | 1) MD, 0.28[-4.67,5.23], NS‡ | Parallel |
| | | n.r. | | | 2) Activities of daily living (tinnitus, auditory, concomitant symptoms) | 2) Tinnitus, MD, -0.75 [-1.10, -0.40], P < 0.0001; auditory, MD, -0.73 [-1.25, -0.21], P = 0.006; concomitant symptoms, MD, -0.27[-0.57, 0.03], NS | China |
| 3) Response rate (verbal description of any changes) | 3) RR, 1.14 [0.87, 1.49], NS |
MD: mean difference; ND: Number of days; n.r.: not reported; RR: risk ratio; VAS: visual analogue scale; NS: not significant; †No numerical data available for calculating effect size. We added the results on the base of authors’ results.
‡The original authors reported statistical significance but our calculation failed to do so.
Figure 1Flowchart of the trial selection process. RCT: randomized clinical trial; CCT: non-randomized controlled clinical trial; UCT: uncontrolled clinical trial.
Summary of treatment points, their rationales and adverse events
| Hansen (1982) [ | deqi sensation | 6 | Common: TE21,TE3,TE17, GB2, ipsilateral | TCM theory | n.r. |
| | | | Shi-type (hyper-function tinnitus): plus LR2 | | |
| | | | Xu-type (hypo-function tinnitus): plus KI3 | | |
| Vilholm (1998) [ | deqi sensation | 25 | SI19, GB2,SI17, GV20: bilateral | TCM theory | n.r. |
| | | | Distal points, n.r.: individually, based on the | | |
| | | | differentiation of signs and symptoms, bilateral. | | |
| Jeon (2012) [ | Deqi sensation | 10 | Prone: Bilateral local points: GB12, GB20 | Previous study | n.r. |
| | | | Ipsilateral points: GV14,GV15,GV16,,GV20,GV21 | | |
| | | | Supine: Bilateral: BL2, LI20; | | |
| | | | Ipsilateranl: TE12, TE22, SI19, GB2, TE17, GB7, GV20, EX-HN3 | | |
| Wang (2010) [ | deqi sensation | 6 | Bilateral local points :GB8,TE17,GB2, GB20,GV20 | TCM theory | n.r. |
| | | | Bilateral remote points :TE3,ST36 | | |
| Marks (1984) [ | deqi sensation | 2 | LI4,LI5,SI4,SI5,SI19,KI6,PC9,GB11,GB12,TE17 and auricular point of vertigo | TCM theory | n.r. |
| Okada (2006) [ | n.r. | 1 | Scalp acupuncture at cochleal-vestibular area (bilateral or ipsilateral n.r.) | TCM theory | Significant pain |
| | | | | | during needling, n = 2 (2.6%) |
| de Azevedo (2007) [ | n.r. | 1 | Scalp acupuncture at cochleal-vestibular area (bilateral or ipsilateral n.r.) | TCM theory | n.r. |
| Tan (2007) [ | deqi sensation | 30 | cervical Jiaji ( EX-B 2) | TCM theory | n.r. |
| Jiang (2010) [ | n.r. | 30 | Point EX-HN1(Sishencong),TE21,GB2 | TCM theory | n.r. |
| | | | Unilateral sick: ipsilateral acupoints | | |
| Bilateral sick: bilateral acupoints |
TCM: Traditional Chinese Medicine.
Risk of bias of included RCTs
| Hansen (1982) [ | U | L | L | L | L | U |
| Vilholm (1998) [ | U | U | L | L | U | U |
| Jeon (2012) [ | L | U | L | L | L | L |
| Wang (2010) [ | U | U | L | U | L | L |
| Marks (1984) [ | U | U | L | L | U | U |
| Okada (2006) [ | H | U | L | L | U | U |
| de Azevedo (2007) [ | H | U | L | L | U | U |
| Tan (2007) [ | U | U | U | U | U | L |
| Jiang (2010) [ | L | U | U | U | U | H |
* Domains of quality assessment based on the Cochrane tools for assessing risk of bias.
Abbreviations; L: low risk of bias; H: high risk of bias; U: Unclear (uncertain risk of bias).